Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04409691
Other study ID # SCMC2020
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date July 1, 2020
Est. completion date June 30, 2023

Study information

Verified date June 2020
Source Shanghai Children's Medical Center
Contact Song Gu
Phone 18930830716
Email gusong@shsmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

a phase I trial focusing on safety and efficacy of prednison shock plus sirolimus maintenance in treating Kaposiform hemangioendothelioma (KHE) with Kasabach-Merritt phenomenon (KMP)


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date June 30, 2023
Est. primary completion date January 31, 2023
Accepts healthy volunteers No
Gender All
Age group N/A to 12 Years
Eligibility Inclusion Criteria:

- Kaposiform Hemangioendotheliomas with Kasabach-Merritt Phenomenon

- 0 - 12 years of age at the time of study entry

- Male or female

- Consent of parents (or the person having parental authority in families)

- Signed and dated written informed consent

Exclusion Criteria:

- with hematological diseases

- with other solid tumors

- with hypertension, diabetes, adrenal insufficiency, neurological diseases, liver and kidney

- dysfunction, and cardiopulmonary insufficiency

- with tuberculosis,cytomegalovirus and Epstein-Barr virus infection before the treatment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
prednison and Sirolimus
If the intravenous prednisolone 4 mg / kg / d (one time in the morning and one time in the evening, 2mg / kg body weight each time) is effective, it will be gradually reduced to 2mg / kg / D (one time in the morning and one time in the evening, 1mg / kg body weight each time), gradually converted to oral prednisone of equal dose, and the hormone will be removed within 4-6 weeks. At the same time, the dosage of sirolimus oral liquid is 0.8 mg / m2 twice a day, with an interval of 12 hours, maintaining the blood concentration of 8-15 ng / ml. if there is no intolerable side effect, the treatment will last for 6 months
prednison
Prednison is taken at a dose of 4mg/kg/d. If the hormone treatment is effective, it will be gradually reduced to 2mg / kg / d (one time in the morning and one time in the evening, 1 mg / kg body weight each time), and repeated after 2 months of continuous treatment and 1 month of drug withdrawal.

Locations

Country Name City State
China Shanghai Children's Medical Center Shanghai Jiaotong University School of Medicine Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Children's Medical Center

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary response to treatment Complete Response:
platelets counts is greater than 100×10^9/L. significant volume reduction is greater than 80%. Fibrinogen levels at 2-4g/L. The surface skin of the tumor is lighter or the tumor is softer significantly.
Partial Response:
platelets counts is greater than 40×10^9/L. significant volume reduction is greater than 50%. Fibrinogen levels at less than 50% reduction from baseline. The surface skin of the tumor and palpation of the tumor have no change or less change.
No Response:
platelets counts is less than 40×10^9/L. significant volume reduction is less than 50% or the tumor is bigger. Fibrinogen levels at grater then 50% reduction from baseline. The surface skin of the tumor is darker or the tumor is harder.
6 months after taking the drug
Secondary side effect rate Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 Monitoring patient's clinical biochemical indicators and symptoms 6 months after taking the drug